FDA-cleared profile

Cydar EV

Cydar Ltd. · Fluoroscopy/Angiography · FDA-cleared (510(k))

Authorized purpose: Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.

Clinical role
Overlay of preoperative 3D vessel anatomy onto live fluoroscopy to assist endovascular device positioning.
Images and patients
Fluoroscopy/Angiography · Lower thorax, abdomen, and pelvis; iliac vessels and corresponding veins
Key limitation
Keep in mind: Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.
  • Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Lower thorax, abdomen, and pelvis; iliac vessels and corresponding veins Input: Previously acquired contrast-enhanced diagnostic CT scans and live fluoroscopic images.
  • Who uses it?Intended users: Trained physicians and qualified endovascular procedure staff.
  • What does the software produce?Output: Registered vascular overlays, stored roadmaps, snapshots, and image guidance for guidewire, catheter, and device positioning.
  • What is its most important limitation?Key limitation: Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.

Clinical takeaway. Clinical role: Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification testing (including registration accuracy calculated from images of the vertebral anatomy) and software validation testing including usability testing with representative clinical users, plus a multi-centre observational clinical study whose primary endpoints were accuracy, robustness, usability, procedure time, radiation exposure, and iodinated contrast volume; it states the clinical endpoint and user feedback data supported the hypothesis of clinical effectiveness. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Overlay of preoperative 3D vessel anatomy onto live fluoroscopy to assist endovascular device positioning.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Previously acquired contrast-enhanced diagnostic CT scans and live fluoroscopic images.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Registered vascular overlays, stored roadmaps, snapshots, and image guidance for guidewire, catheter, and device positioning.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Operating-room and interventional procedure environments using compatible fluoroscopy and CT planning.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained physicians and qualified endovascular procedure staff.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports software verification testing (including registration accuracy calculated from images of the vertebral anatomy) and software validation testing including usability testing with representative clinical users, plus a multi-centre observational clinical study whose primary endpoints were accuracy, robustness, usability, procedure time, radiation exposure, and iodinated contrast volume; it states the clinical endpoint and user feedback data supported the hypothesis of clinical effectiveness. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software verification testing has been performed in accordance with the software verification plan to cover the system requirements at system/integration and unit levels" … "registration accuracy calculated from images of the vertebral anatomy as documented in". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports software verification testing (including registration accuracy calculated from images of the vertebral anatomy) and software validation testing including usability testing with representative clinical users, plus a multi-centre observational clinical study whose primary endpoints were accuracy, robustness, usability, procedure time, radiation exposure, and iodinated contrast volume; it states the clinical endpoint and user feedback data supported the hypothesis of clinical effectiveness. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software verification testing has been performed in accordance with the software verification plan to cover the system requirements at system/integration and unit levels" … "registration accuracy calculated from images of the vertebral anatomy as documented in". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K160088 FDA evidence package for Cydar EV

  • DesignFDA 510(k) non-clinical performance and clinical investigation support for image guidance and registration.
  • PopulationLower thorax, abdomen, and pelvis; iliac vessels and corresponding veins
  • Scopeexact submission
  • Tested versionCydar EV configuration described in K160088
  • IndependenceSponsor or vendor study

K160088

The public summary describes standards and clinical investigation support but does not establish a general clinical-outcome benefit or a current service-level commitment.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K160088 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Previously acquired contrast-enhanced diagnostic CT scans and live fluoroscopic images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) K160088: Cydar EV

  2. Routing

    Source context, not route validation: The FDA package describes contrast-enhanced CT input, live fluoroscopy, 2D-3D registration using vertebral anatomy, stored roadmaps and snapshots, and application of DICOM standards.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) K160088: Cydar EV

  3. AI processing

    Source context, not route validation: The FDA package describes a software-only solution with cloud communication, storage, and processing accessed over private networks or the public Internet and recommended hardware; current provider, hosting, contract, availability, and security details remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) K160088: Cydar EV

  4. Returned objects

    Source context, not route validation: Registered vascular overlays, stored roadmaps, snapshots, and image guidance for guidewire, catheter, and device positioning.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) K160088: Cydar EV

  5. Viewer/worklist/report

    Unresolved route: Registered vascular overlays, stored roadmaps, snapshots, and image guidance for guidewire, catheter, and device positioning.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) K160088: Cydar EV

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes a software-only solution with cloud communication, storage, and processing accessed over private networks or the public Internet and recommended hardware; current provider, hosting, contract, availability, and security details remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA package describes contrast-enhanced CT input, live fluoroscopy, 2D-3D registration using vertebral anatomy, stored roadmaps and snapshots, and application of DICOM standards.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only trained physicians and qualified endovascular procedure staff should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K160088 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K160088 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The FDA package describes a software-only solution with cloud communication, storage, and processing accessed over private networks or the public Internet and recommended hardware; current provider, hosting, contract, availability, and security details remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes contrast-enhanced CT input, live fluoroscopy, 2D-3D registration using vertebral anatomy, stored roadmaps and snapshots, and application of DICOM standards.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K160088 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. fluoroscopy-guided vascular image-navigation software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K160088
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Fluoroscopy/Angiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Lower thorax, abdomen, and pelvis; iliac vessels and corresponding veins
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2016-07-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
3Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Three PubMed records and one trial record were screened. They concern Cydar EV, Cydar EV Intelligent Maps, or an AI image-fusion workflow, but none identifies the tested software as the exact K160088 configuration; all four records are quarantined. The current discovery snapshot contains 3 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA 510(k) K160088: Cydar EV

    U.S. Food and Drug Administration - Published 2016-07-07 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K160088 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K210807

FlightPlan for Liver

GE Medical Systems SCS

Authorized purpose: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.

Modality
Fluoroscopy/Angiography
Anatomy
Liver; hepatic arterial vasculature and hypervascular liver lesions
Decision
2021-10-22
FDA-cleared K260077

OrthoGrid Hip AI® 4.0

OrthoGrid Systems, Inc.

Authorized purpose: OrthoGrid Hip AI 4.0 analyzes two-dimensional C-arm fluoroscopic images to assist positioning of hip-replacement components during direct-anterior total hip arthroplasty.

Modality
Fluoroscopy/Angiography
Anatomy
Hip
Decision
2026-05-29
FDA-cleared K252503

Intelligent NR

Canon, Inc.

Authorized purpose: Canon Intelligent NR is a noise-reduction function for fluoroscopic images acquired on compatible Canon radiography and fluoroscopy systems.

Modality
Fluoroscopy/Angiography
Anatomy
Whole body; diagnostic and interventional anatomy
Decision
2026-04-30
FDA-cleared K252099

Trinias

Shimadzu Corporation

Authorized purpose: Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.

Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Decision
2026-03-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history